CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Updates on Acquisition
As per the attached letter.31-03-2021
31-03-2021
Cadila's investors hope for US growth, vaccine success
Cadila's prospects in the Indian market can get a further boost from the success of its indigenous covid-19 vaccine28-03-2021
Cadila Healthcare Ltd - 532321 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Loss of Share Certificate26-03-2021
CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Acquisition
Acquisition25-03-2021
CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus Cadila receives tentative approval from the USFDA for Emtricitabine and Tenofovir Disoproxil Fumarate Tablets25-03-2021
Zydus Cadila slashes price of remdesivir to 899 per dose
RemdacTM has been one of the critical drugs in the disease management on COVID and we hope that this price cut will enable people from every strata of the society to access this critical drug, MD of Zydus Cadila said24-03-2021
Cadila Health settles patents case with US firm over anti-cancer drug Revlimid
Bristol Myers Squibb (BMS), the parent of Celgene, had in 2020 garnered over $12 billion in sales from the drug, making it the largest drug in terms of sales for the parent, according to BMS' financial statements for the year24-03-2021
Cadila Healthcare Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Please find enclosed a copy of press release dated March 24, 2021 titled 'RemdacTM (Remdesivir) from Zydus now more affordable at Rs.899'. Signed covering letter is attached.24-03-2021
CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Please find enclosed a copy of press release dated March 24, 2021 titled 'RemdacTM (Remdesivir) from Zydus now more affordable at Rs.899'.24-03-2021